Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional chinese medicine

Cancer Genomics and Proteomics

Volumn 7, Issue 4, 2010, Pages 191-206

  Mahringer, Anne ^a   Karamustafa, Shirin ^b   Klotz, Daniel ^b   Kahl, Stefan ^c   Konkimalla, V Badireenath ^b   Wang, Yifen ^d   Wang, Junsong ^d   Liu, Hai Yang ^d   Boechzelt, Herbert ^e   Hao, Xiaojiang ^d   Bauer, Rudolf ^c   Fricker, Gert ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

^d KUNMING INSTITUTE OF BOTANY   (China)

^e JOANNEUM RESEARCH   (Austria)

Author keywords

Bufadienolides; Calcein assay; Multidrug resistance; Natural products; P glycoprotein; Pharmacogenomics; Phytochemicals

Indexed keywords

4 METHOXY[2,3 B]QUINOLINE; BAICALEIN; BAICALIN; BERBERINE; BIOCHANIN A; BUFALIN; CANTHARIDIN; CARBALEXINE C; DEOXYSEROFENDIC ACID; DIOSMETIN; ENT 15 ATISEN 19 OIC ACID; ENT 16 ATISEN 19 OIC ACID; GINGEROL; GINSENOSIDE RH 2; GLYBOMINE A; GLYBOMINE B; GLYCOBORININE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HOMOHARRINGTONINE; ISOSCOPOLETIN; NARDOFURAN; PLANT MEDICINAL PRODUCT; SCILLARENIN; SCOPOLETIN; SHOGAOL; TACCAOSIDE C; TACCAOSIDE D; TRANS COUMAROYLTYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; HERBACEOUS AGENT; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CANCER CELL; CHINESE MEDICINE; CLUSTER ANALYSIS; CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENDOTHELIUM CELL; FLUORESCENCE ANALYSIS; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN TRANSPORT; SWINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM;

ANIMALS; BLOOD-BRAIN BARRIER; CELL PROLIFERATION; CELLS, CULTURED; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; SWINE;

EID: 77955970524     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Loscher W and Potschka H: Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6: 591-602, 2005.
2. Ballabh P, Braun A and Nedergaard M: The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16: 1-13, 2004
3. Schinkel AH, Wagenaar E, Mol CA and van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524, 1996.
4. Miller DS: Confocal imaging of xenobiotic transport across the blood-brain barrier. J Exp Zoolog A Comp Exp Biol 300: 84-90, 2003.
5. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W and de Vries EG: The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Res 26: 449-462, 2000.
6. Hermann DM, Kilic E, Spudich A, Kramer SD, Wunderli-Allenspach H and Bassetti CL: Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 60: 489-498, 2006.
7. Fromm MF: Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423-429, 2004.
8. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
9. Ford JM, Yang JM and Hait WN: P-Glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res 87: 3-38, 1996.
10. Schinkel AH and Jonker JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29, 2003.
11. Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12: 273-286, 2006.
12. Kreuter J: Nanoparticles - a historical perspective. Int J Pharm 331: 1-10, 2007.
13. Bickel U, Yoshikawa T and Pardridge WM: Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 46: 247-279, 2001.
14. Nobili S, Landini I, Giglioni B and Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7: 861-879, 2006.
15. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A and Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110: 1309-1318, 2002.
16. Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D and Vickers AE: The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26: 802-811, 1998.
17. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM and Schellens JH: Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943-2950, 2002.
18. Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA and Schellens JH: Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 10: 7220-7228, 2004.
19. Efferth T, Fu YJ, Zu YG, Schwarz G, Konkimalla VS and Wink M: Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr Med Chem 14: 2024-2032, 2007.
20. Efferth T, Miyachi H and Bartsch H: Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics 4: 81-91, 2007.
21. Efferth T, Li PC, Konkimalla VS and Kaina B: From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 13: 353-361, 2007.
22. Efferth T, Kahl S, Paulus K, Adams M, Rauh R, Boechzelt H, Hao X, Kaina B and Bauer R: Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther 7: 152-161, 2008.
23. Wang J, Di Y, Yang X, Li S, Wang Y and Hao X: Hydroquinone diglycoside acyl esters from the stems of Glycosmis pentaphylla. Phytochemistry 67: 486-491, 2006.
24. Wang YF, Lai GF, Efferth T, Cao JX and Luo SD: New glycosides from Tetracentron sinense and their cytotoxic activity. Chem Biodivers 3: 1023-1030, 2006.
25. Hu M, Chen J and Lin H: Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J Pharmacol Exp Ther 307: 314-321, 2003.
26. Fricker G and Miller DS: Modulation of drug transporters at the blood-brain barrier. Pharmacology 70: 169-176, 2004.
27. Huwyler J, Drewe J, Klusemann C and Fricker G: Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol 118: 1879-1885, 1996.
28. Bauer B, Miller DS and Fricker G: Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm Res 20: 1170-1176, 2003.
29. Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V and Remacle J: Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 64: 8987-8993, 2004.
30. Schramm U, Fricker G, Wenger R and Miller DS: P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules. Am J Physiol 268: F46-F52, 1995.
31. Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H and Niethammer D: Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res 50: 6793-6799, 1990.
32. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E and Davey R: Activity of drugs from traditional Chinese medicine towards sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 28: 160-168, 2002.
33. Seelig A: A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251: 252-261, 1998.
34. Seelig A and Landwojtowicz E: Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12: 31-40, 2000.
35. Bubik M, Ott M, Mahringer A and Fricker G: Rapid assessment of P-glycoprotein-drug interactions at the blood-brain barrier. Anal Biochem 358: 51-58, 2006.
36. Eneroth A, Astrom E, Hoogstraate J, Schrenk D, Conrad S, Kauffmann HM and Gjellan K: Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci 12: 205-214, 2001.
37. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000.
38. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN and Bates SE: Identification of epidermal growth factor receptor and erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89: 1505-1515, 1997.
39. Efferth T and Volm M: Protein expression profiles indicative for drug resistance of kidney carcinoma. Cancer Genomics Proteomics 1: 17-22, 2004.
40. Volm M, Koomägi R and Efferth T: Prediction of drug sensitivity and resistance of cancer by protein expression profiling. Cancer Genomics Proteomics 1: 157-166, 2004.
41. Efferth T, Koomägi R, Mattern J and Volm M: Lung cancer protein expression profiles of smokers and non-smokers. Cancer Genomics Proteomics 1: 249-254, 2004.
42. Efferth T and Kaina B: Microarray-based prediction of cytotoxicity of tumor cells to arsenic trioxide. Cancer Genomics Proteomics 1: 363-370, 2004.
43. Efferth T, Chen Z, Kaina B and Wang G: Molecular determinants of response of tumor cells to berberine. Cancer Genomics Proteomics 2: 115-124, 2005.
44. Morris ME and Zhang S: Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 78: 2116-2130, 2006.
45. Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, Zintl F, Mattern J and Volm M: Prediction of broad-spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 14: 2405-2412, 2008.
46. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N and Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197-204, 2003.
47. Kemper EM, Boogerd W, Thuis I, Beijnen JH and van Tellingen O: Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 30: 415-423, 2004.
48. Lee G, Dallas S, Hong M and Bendayan R: Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 53: 569-596, 2001.
49. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
50. Rautio J, Humphreys JE and Webster LO: In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34: 786-792, 2006.
51. Ayesh S, Shao YM and Stein WD: Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316: 8-18, 1996.
52. Borgnia MJ, Eytan GD and Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271: 3163-3171, 1996.
53. Safa AR: Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents 4: 1-17, 2004.
54. Globisch C, Pajeva IK and Wiese M: Identification of putative binding sites of P-glycoprotein based on its homology model. Chem Med Chem 3: 280-295, 2008.
55. Shapiro AB and Ling V: Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur J Biochem 250: 122-129, 1997.
56. Loo TW, Bartlett MC and Clarke DM: Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein. J Biol Chem 279: 18232-18238, 2004.
57. Ramu A, Pollard HB and Rosario LM: Doxorubicin resistance in P388 leukemia-evidence for reduced drug influx. Int J Cancer 44: 539-547, 1989.
58. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR and Bonnet JD: A phase II randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75: 815-820, 1995.
59. Baer MR, George SL and Dodge RK: Phase 3 study of the multidrug-resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100: 1224-1232, 2002.